{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T10:34:42Z","timestamp":1775039682077,"version":"3.50.1"},"reference-count":121,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2022,3,18]],"date-time":"2022-03-18T00:00:00Z","timestamp":1647561600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Acute myeloid leukemia (AML) is the most common acute leukemia in adults. The standard of care in medically and physically fit patients is intensive induction therapy. The majority of these intensively treated patients achieve a complete remission. However, a high number of these patients will experience relapse. In patients older than 60 years, the results are even worse. Therefore, new therapeutic approaches are desperately needed. One promising approach in high-risk leukemia to prevent relapse is the induction of the immune system simultaneously or after reduction of the initial tumor burden. Different immunotherapeutic approaches such as allogenic stem cell transplantation or donor lymphocyte infusions are already standard therapies, but other options for AML treatment are in the pipeline. Moreover, the therapeutic landscape in AML is rapidly changing, and in the last years, a number of immunogenic targets structures eligible for specific therapy, risk assessment or evaluation of disease course were determined. For example, leukemia-associated antigens (LAA) showed to be critical as biomarkers of disease state and survival, as well as markers of minimal residual disease (MRD). Yet many mechanisms and properties are still insufficiently understood, which also represents a great potential for this form of therapy. Therefore, targeted therapy as immunotherapy could turn into an efficient tool to clear residual disease, improve the outcome of AML patients and reduce the relapse risk. In this review, established but also emerging immunotherapeutic approaches for AML patients will be discussed.<\/jats:p>","DOI":"10.3390\/ijms23063304","type":"journal-article","created":{"date-parts":[[2022,3,20]],"date-time":"2022-03-20T21:30:14Z","timestamp":1647811814000},"page":"3304","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Increasing Role of Targeted Immunotherapies in the Treatment of AML"],"prefix":"10.3390","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1256-173X","authenticated-orcid":false,"given":"Jochen","family":"Greiner","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Diakonie Hospital Stuttgart, 70176 Stuttgart, Germany"},{"name":"Department of Internal Medicine III, University of Ulm, 89081 Ulm, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marlies","family":"G\u00f6tz","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine III, University of Ulm, 89081 Ulm, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Verena","family":"Wais","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine III, University of Ulm, 89081 Ulm, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,3,18]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1056\/NEJMra1406184","article-title":"Acute Myeloid Leukemia","volume":"373","author":"Weisdorf","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"Estey","year":"2017","journal-title":"Blood"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/s41409-018-0286-2","article-title":"Post-remission strategies for the prevention of relapse following allogeneic hematopoietic cell transplantation for high-risk acute myeloid leukemia: Expert review from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation","volume":"54","author":"Lee","year":"2019","journal-title":"Bone Marrow Transplant."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.ccell.2015.03.001","article-title":"Immune checkpoint blockade: A common denominator approach to cancer therapy","volume":"27","author":"Topalian","year":"2015","journal-title":"Cancer Cell"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"30","DOI":"10.3324\/haematol.2016.150656","article-title":"The emerging role of immune checkpoint inhibition in malignant lymphoma","volume":"102","author":"Hude","year":"2017","journal-title":"Haematologica"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1801946","article-title":"Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden","volume":"378","author":"Hellmann","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/tan.13005","article-title":"Hematopoietic stem cell transplantation and cellular therapy","volume":"89","author":"Kolb","year":"2017","journal-title":"HLA"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1182\/asheducation-2017.1.693","article-title":"Graft versus tumor effects and why people relapse","volume":"2017","author":"Falkenburg","year":"2017","journal-title":"Educ. Program Am. Soc. Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1172\/JCI129204","article-title":"Immune escape and immunotherapy of acute myeloid leukemia","volume":"130","author":"Vago","year":"2020","journal-title":"J. Clin. Investig."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Greiner, J. (2019). The Important Role of Immunotherapies in Acute Myeloid Leukemia. J. Clin. Med., 8.","DOI":"10.3390\/jcm8122054"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1158\/1078-0432.CCR-11-2524","article-title":"PRAME-induced inhibition of retinoic acid receptor signaling-mediated differentiation\u2014A possible target for ATRA response in AML without t(15;17)","volume":"19","author":"Bullinger","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1038\/leu.2012.145","article-title":"Leukemia-associated antigens and their relevance to the immunotherapy of acute myeloid leukemia","volume":"26","author":"Anguille","year":"2012","journal-title":"Leukemia"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1002\/ijc.29583","article-title":"Leukemic progenitor cells are susceptible to targeting by stimulated cytotoxic T cells against immunogenic leukemia-associated antigens","volume":"137","author":"Schneider","year":"2015","journal-title":"Int. J. Cancer."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1177\/117727190700200015","article-title":"Leukemia associated antigens: Their dual role as biomarkers and immunotherapeutic targets for acute myeloid leukemia","volume":"2","author":"Guinn","year":"2007","journal-title":"Biomark. Insights"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"4109","DOI":"10.1182\/blood-2006-01-023127","article-title":"Expression of tumor-associated antigens in acute myeloid leukemia: Implications for specific immunotherapeutic approaches","volume":"108","author":"Greiner","year":"2006","journal-title":"Blood"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1093\/biolre\/ioab074","article-title":"The PRAME family of cancer testis antigens is essential for germline development and gametogenesisdagger","volume":"105","author":"Kern","year":"2021","journal-title":"Biol. Reprod."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e12770","DOI":"10.1111\/cpr.12770","article-title":"The role of the cancer testis antigen PRAME in tumorigenesis and immunotherapy in human cancer","volume":"53","author":"Xu","year":"2020","journal-title":"Cell Prolif."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1111\/bjh.12352","article-title":"High and low, but not intermediate, PRAME expression levels are poor prognostic markers in myelodysplastic syndrome at disease presentation","volume":"162","author":"Liberante","year":"2013","journal-title":"Br. J. Haematol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1038\/leu.2016.254","article-title":"PR1 peptide vaccine induces specific immunity with clinical responses in myeloid malignancies","volume":"31","author":"Qazilbash","year":"2017","journal-title":"Leukemia"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"201","DOI":"10.3389\/fimmu.2015.00201","article-title":"Interactions between Hyaluronan and Its Receptors (CD44, RHAMM) Regulate the Activities of Inflammation and Cancer","volume":"6","author":"Misra","year":"2015","journal-title":"Front. Immunol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"16667","DOI":"10.1074\/jbc.M702078200","article-title":"The hyaluronan receptors CD44 and Rhamm (CD168) form complexes with ERK1,2 that sustain high basal motility in breast cancer cells","volume":"282","author":"Hamilton","year":"2007","journal-title":"J. Biol. Chem."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1242\/jcs.022038","article-title":"Cell-surface and mitotic-spindle RHAMM: Moonlighting or dual oncogenic functions?","volume":"121","author":"Maxwell","year":"2008","journal-title":"J. Cell Sci."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S0301-472X(02)00874-3","article-title":"Receptor for hyaluronan acid-mediated motility (RHAMM) is a new immunogenic leukemia-associated antigen in acute and chronic myeloid leukemia","volume":"30","author":"Greiner","year":"2002","journal-title":"Exp. Hematol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1182\/blood-2004-12-4787","article-title":"Identification and characterization of epitopes of the receptor for hyaluronic acid-mediated motility (RHAMM\/CD168) recognized by CD8+ T cells of HLA-A2-positive patients with acute myeloid leukemia","volume":"106","author":"Greiner","year":"2005","journal-title":"Blood"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"5195","DOI":"10.1200\/JCO.2009.22.4865","article-title":"Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: A European LeukemiaNet study","volume":"27","author":"Cilloni","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"672","DOI":"10.3324\/haematol.2015.141796","article-title":"Wilms tumor 1 mutations in the pathogenesis of acute myeloid leukemia","volume":"101","author":"Rampal","year":"2016","journal-title":"Haematologica"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1080\/10428194.2020.1762884","article-title":"Wilms\u2019 tumor 1 gene in hematopoietic malignancies: Clinical implications and future directions","volume":"61","author":"Luo","year":"2020","journal-title":"Leuk. Lymphoma"},{"key":"ref_29","first-page":"36","article-title":"Review of the Results of WT1 Peptide Vaccination Strategies for Myelodysplastic Syndromes and Acute Myeloid Leukemia from Nine Different Studies","volume":"6","author":"Jimenez","year":"2015","journal-title":"Front. Immunol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s12935-016-0326-1","article-title":"Survivin: A unique target for tumor therapy","volume":"16","author":"Garg","year":"2016","journal-title":"Cancer Cell Int."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Greiner, J., Brown, E., Bullinger, L., Hills, R.K., Morris, V., D\u00f6hner, H., Mills, K.I., and Guinn, B.A. (2021). Survivin\u2019 Acute Myeloid Leukaemia-A Personalised Target for inv(16) Patients. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms221910482"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/nrc2293","article-title":"Survivin, cancer networks and pathway-directed drug discovery","volume":"8","author":"Altieri","year":"2008","journal-title":"Nat. Rev. Cancer"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"8014","DOI":"10.1158\/0008-5472.CAN-07-1343","article-title":"YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts","volume":"67","author":"Nakahara","year":"2007","journal-title":"Cancer Res."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1016\/j.jmb.2017.03.005","article-title":"A Comprehensive Guide to the MAGE Family of Ubiquitin Ligases","volume":"429","author":"Lee","year":"2017","journal-title":"J. Mol. Biol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"16121","DOI":"10.1074\/jbc.REV120.008029","article-title":"Emerging roles of the MAGE protein family in stress response pathways","volume":"295","author":"Chen","year":"2020","journal-title":"J. Biol. Chem."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/j.leukres.2010.02.004","article-title":"The DNA demethylating agent 5-aza-2\u2019-deoxycytidine induces expression of NY-ESO-1 and other cancer\/testis antigens in myeloid leukemia cells","volume":"34","author":"Almstedt","year":"2010","journal-title":"Leuk. Res."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1002\/ijc.32028","article-title":"Targeting the arginine metabolic brake enhances immunotherapy for leukaemia","volume":"145","author":"Mussai","year":"2019","journal-title":"Int. J. Cancer"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1182\/blood-2008-09-178848","article-title":"Elevated expression of the leukemia-associated antigen SSX2IP predicts survival in acute myeloid leukemia patients who lack detectable cytogenetic rearrangements","volume":"113","author":"Guinn","year":"2009","journal-title":"Blood"},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Davis, L., Mills, K.I., Orchard, K.H., and Guinn, B.A. (2020). Identification of Genes Whose Expression Overlaps Age Boundaries and Correlates with Risk Groups in Paediatric and Adult Acute Myeloid Leukaemia. Cancers, 12.","DOI":"10.3390\/cancers12102769"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2040620719860645","DOI":"10.1177\/2040620719860645","article-title":"Novel therapy in Acute myeloid leukemia (AML): Moving toward targeted approaches","volume":"10","author":"Winer","year":"2019","journal-title":"Ther. Adv. Hematol."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Khan, G.N., Orchard, K., and Guinn, B.A. (2019). Antigenic Targets for the Immunotherapy of Acute Myeloid Leukaemia. J. Clin. Med., 8.","DOI":"10.3390\/jcm8020134"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1182\/blood-2007-07-099366","article-title":"RHAMM-R3 peptide vaccination in patients with acute myeloid leukemia, myelodysplastic syndrome, and multiple myeloma elicits immunologic and clinical responses","volume":"111","author":"Schmitt","year":"2008","journal-title":"Blood"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.3324\/haematol.2009.014704","article-title":"High-dose RHAMM-R3 peptide vaccination for patients with acute myeloid leukemia, myelodysplastic syndrome and multiple myeloma","volume":"95","author":"Greiner","year":"2010","journal-title":"Haematologica"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"6541","DOI":"10.1182\/blood-2009-02-202598","article-title":"A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS","volume":"113","author":"Keilholz","year":"2009","journal-title":"Blood"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1182\/bloodadvances.2017014175","article-title":"Phase 2 trial of a multivalent WT1 peptide vaccine (galinpepimut-S) in acute myeloid leukemia","volume":"2","author":"Maslak","year":"2018","journal-title":"Blood Adv."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1002\/ajh.24014","article-title":"WT1 vaccination in AML and MDS: A pilot trial with synthetic analog peptides","volume":"90","author":"Brayer","year":"2015","journal-title":"Am. J. Hematol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.omtm.2017.03.004","article-title":"Dendritic Cell Therapies for Hematologic Malignancies","volume":"5","author":"Weinstock","year":"2017","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1182\/blood-2017-04-780155","article-title":"Dendritic cell vaccination as postremission treatment to prevent or delay relapse in acute myeloid leukemia","volume":"130","author":"Anguille","year":"2017","journal-title":"Blood"},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Van Acker, H.H., Versteven, M., Lichtenegger, F.S., Roex, G., Campillo-Davo, D., Lion, E., Subklewe, M., Van Tendeloo, V.F., Berneman, Z.N., and Anguille, S. (2019). Dendritic Cell-Based Immunotherapy of Acute Myeloid Leukemia. J. Clin. Med., 8.","DOI":"10.3390\/jcm8050579"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"e1200","DOI":"10.1002\/cti2.1200","article-title":"Ex vivo enrichment of PRAME antigen-specific T cells for adoptive immunotherapy using CD137 activation marker selection","volume":"9","author":"Lee","year":"2020","journal-title":"Clin. Transl. Immunol."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Klobuch, S., Hammon, K., Vatter-Leising, S., Neidlinger, E., Zwerger, M., Wandel, A., Neuber, L.M., Heilmeier, B., Fichtner, R., and Mirbeth, C. (2020). HLA-DPB1 Reactive T Cell Receptors for Adoptive Immunotherapy in Allogeneic Stem Cell Transplantation. Cells, 9.","DOI":"10.3390\/cells9051264"},{"key":"ref_52","unstructured":"ClinicalTrials.gov (2022, March 08). Identifier: NCT03503968. TCR Modified T Cells MDG1011 in High Risk Myeloid and Lymphoid Neoplasms, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03503968."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/s41571-021-00509-w","article-title":"Towards precision medicine for AML","volume":"18","author":"Wei","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/s41375-018-0357-9","article-title":"Targeting FLT3 mutations in AML: Review of current knowledge and evidence","volume":"33","author":"Daver","year":"2019","journal-title":"Leukemia"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1182\/blood.2019002697","article-title":"Impact of NPM1\/FLT3-ITD genotypes defined by the 2017 European LeukemiaNet in patients with acute myeloid leukemia","volume":"135","author":"Thiede","year":"2020","journal-title":"Blood"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"4945","DOI":"10.1182\/bloodadvances.2020002904","article-title":"Midostaurin in patients with acute myeloid leukemia and FLT3-TKD mutations: A subanalysis from the RATIFY trial","volume":"4","author":"Voso","year":"2020","journal-title":"Blood Adv."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"2985","DOI":"10.1182\/blood-2006-07-032839","article-title":"A neoepitope generated by an FLT3 internal tandem duplication (FLT3-ITD) is recognized by leukemia-reactive autologous CD8+ T cells","volume":"109","author":"Graf","year":"2007","journal-title":"Blood"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1038\/s41375-018-0009-0","article-title":"CAR T-cells targeting FLT3 have potent activity against FLT3(-)ITD(+) AML and act synergistically with the FLT3-inhibitor crenolanib","volume":"32","author":"Jetani","year":"2018","journal-title":"Leukemia"},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Schmied, B.J., Lutz, M.S., Riegg, F., Zekri, L., Heitmann, J.S., Buhring, H.J., Jung, G., and Salih, H.R. (2019). Induction of NK Cell Reactivity against B-Cell Acute Lymphoblastic Leukemia by an Fc-Optimized FLT3 Antibody. Cancers, 11.","DOI":"10.3390\/cancers11121966"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.stemcr.2020.05.013","article-title":"Chromatin Complexes Maintain Self-Renewal of Myeloid Progenitors in AML: Opportunities for Therapeutic Intervention","volume":"15","author":"Uckelmann","year":"2020","journal-title":"Stem Cell Rep."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1182\/bloodadvances.2020003734","article-title":"Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed\/refractory AML","volume":"5","author":"Stahl","year":"2021","journal-title":"Blood Adv."},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Forghieri, F., Comoli, P., Marasca, R., Potenza, L., and Luppi, M. (2018). Minimal\/Measurable Residual Disease Monitoring in NPM1-Mutated Acute Myeloid Leukemia: A Clinical Viewpoint and Perspectives. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19113492"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1182\/blood.2021013626","article-title":"2021 Update on MRD in acute myeloid leukemia: A consensus document from the European LeukemiaNet MRD Working Party","volume":"138","author":"Heuser","year":"2021","journal-title":"Blood"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1038\/leu.2014.116","article-title":"Leukemic stem cells of acute myeloid leukemia patients carrying NPM1 mutation are candidates for targeted immunotherapy","volume":"28","author":"Schneider","year":"2014","journal-title":"Leukemia"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1182\/blood-2013-04-496844","article-title":"Immune responses against the mutated region of cytoplasmatic NPM1 might contribute to the favorable clinical outcome of AML patients with NPM1 mutations (NPM1mut)","volume":"122","author":"Greiner","year":"2013","journal-title":"Blood"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1172\/JCI97482","article-title":"Mutated nucleophosmin 1 as immunotherapy target in acute myeloid leukemia","volume":"129","author":"Reijmers","year":"2019","journal-title":"J. Clin. Investig."},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Narayan, R., Olsson, N., Wagar, L.E., Medeiros, B.C., Meyer, E., Czerwinski, D., Khodadoust, M.S., Zhang, L., Schultz, L., and Davis, M.M. (2019). Acute myeloid leukemia immunopeptidome reveals HLA presentation of mutated nucleophosmin. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0219547"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1182\/blood-2011-11-394395","article-title":"Mutated regions of nucleophosmin 1 elicit both CD4(+) and CD8(+) T-cell responses in patients with acute myeloid leukemia","volume":"120","author":"Greiner","year":"2012","journal-title":"Blood"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.ccell.2018.08.005","article-title":"Mutant NPM1 Maintains the Leukemic State through HOX Expression","volume":"34","author":"Brunetti","year":"2018","journal-title":"Cancer Cell"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1080\/17512433.2018.1478725","article-title":"Gemtuzumab ozogamicin for the treatment of acute myeloid leukemia","volume":"11","author":"Baron","year":"2018","journal-title":"Expert Rev. Clin. Pharm."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1016\/S0140-6736(12)60485-1","article-title":"Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): A randomised, open-label, phase 3 study","volume":"379","author":"Castaigne","year":"2012","journal-title":"Lancet"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1200\/JCO.19.01406","article-title":"Gemtuzumab Ozogamicin in NPM1-Mutated Acute Myeloid Leukemia: Early Results From the Prospective Randomized AMLSG 09-09 Phase III Study","volume":"38","author":"Schlenk","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.1182\/blood.2020005998","article-title":"Impact of gemtuzumab ozogamicin on MRD and relapse risk in patients with NPM1-mutated AML: Results from the AMLSG 09-09 trial","volume":"136","author":"Weber","year":"2020","journal-title":"Blood"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"S67","DOI":"10.1016\/S2152-2650(20)30466-3","article-title":"Targeting CD123 in AML","volume":"20","author":"Lane","year":"2020","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1038\/s41591-020-0910-8","article-title":"Targeting CD70 with cusatuzumab eliminates acute myeloid leukemia stem cells in patients treated with hypomethylating agents","volume":"26","author":"Riether","year":"2020","journal-title":"Nat. Med."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"101221","DOI":"10.1016\/j.beha.2020.101221","article-title":"The promise of macrophage directed checkpoint inhibitors in myeloid malignancies","volume":"33","author":"Swoboda","year":"2020","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1182\/blood-2021-153638","article-title":"Phase I\/II Study of Azacitidine (AZA) with Venetoclax (VEN) and Magrolimab (Magro) in Patients (pts) with Newly Diagnosed Older\/Unfit or High-Risk Acute Myeloid Leukemia (AML) and Relapsed\/Refractory (R\/R) AML","volume":"138","author":"Daver","year":"2021","journal-title":"Blood"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"S290","DOI":"10.1016\/S2152-2650(21)01694-3","article-title":"AML-196: The First-in-Class Anti-CD47 Antibody Magrolimab in Combination with Azacitidine Is Well Tolerated and Effective in AML Patients: Phase 1b Results","volume":"21","author":"Sallman","year":"2021","journal-title":"Clin. Lymphoma Myeloma Leuk. Abstr."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"697","DOI":"10.3389\/fonc.2020.00697","article-title":"CAR T Cells for Acute Myeloid Leukemia: State of the Art and Future Directions","volume":"10","author":"Mardiana","year":"2020","journal-title":"Front. Oncol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"e321","DOI":"10.1634\/theoncologist.2019-0233","article-title":"The European Medicines Agency Review of Kymriah (Tisagenlecleucel) for the Treatment of Acute Lymphoblastic Leukemia and Diffuse Large B-Cell Lymphoma","volume":"25","author":"Ali","year":"2020","journal-title":"Oncologist"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"e168","DOI":"10.1016\/S1470-2045(19)30823-X","article-title":"CAR T cells: Continuation in a revolution of immunotherapy","volume":"21","author":"Singh","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1097\/CCO.0000000000000653","article-title":"New targets and technologies for CAR-T cells","volume":"32","author":"Freitag","year":"2020","journal-title":"Curr. Opin. Oncol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1002\/ijc.33002","article-title":"B-cell maturation antigen-specific chimeric antigen receptor T cells for multiple myeloma: Clinical experience and future perspectives","volume":"147","author":"Sellner","year":"2020","journal-title":"Int. J. Cancer"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"656218","DOI":"10.3389\/fonc.2021.656218","article-title":"Immunotherapy in Acute Myeloid Leukemia: Where We Stand","volume":"11","author":"Isidori","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Greiner, J., Gotz, M., Bunjes, D., Hofmann, S., and Wais, V. (2019). Immunological and Clinical Impact of Manipulated and Unmanipulated DLI after Allogeneic Stem Cell Transplantation of AML Patients. J. Clin. Med., 9.","DOI":"10.3390\/jcm9010039"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41409-018-0227-0","article-title":"Prevention and treatment of relapse after stem cell transplantation by cellular therapies","volume":"54","author":"Falkenburg","year":"2019","journal-title":"Bone Marrow Transplant."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1002\/ijc.31753","article-title":"Donor lymphocyte infusion leads to diversity of specific T cell responses and reduces regulatory T cell frequency in clinical responders","volume":"144","author":"Hofmann","year":"2019","journal-title":"Int. J. Cancer"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.leukres.2010.03.013","article-title":"Immunogenic antigens as therapeutic targets against myeloid leukaemic cells","volume":"34","author":"Hofmann","year":"2010","journal-title":"Leuk. Res."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1159\/000328898","article-title":"Adoptive Immunotherapy after Allogeneic Hematopoietic Progenitor Cell Transplantation: New Perspectives for Transfusion Medicine","volume":"38","author":"Hofmann","year":"2011","journal-title":"Transfus. Med. Hemother."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1182\/blood.2020009471","article-title":"Clinical effects of administering leukemia-specific donor T cells to patients with AML\/MDS after allogeneic transplant","volume":"137","author":"Lulla","year":"2021","journal-title":"Blood"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"4819","DOI":"10.1182\/blood-2021-152419","article-title":"Preliminary analysis of a phase 1\/2 study of NEXI-001 donor-derived multi-antigen-specific CD8+ T-cells for the treatment of relapsed acute myeloid leukemia (AML) after allogeneic hematopoietic cell transplantation (HCT)","volume":"138","author":"Vasu","year":"2021","journal-title":"Blood"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1080\/17474086.2018.1453802","article-title":"Epigenetic therapy: Azacytidine and decitabine in acute myeloid leukemia","volume":"11","author":"Bohl","year":"2018","journal-title":"Expert Rev. Hematol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"587","DOI":"10.18632\/oncotarget.1782","article-title":"Immune regulation by low doses of the DNA methyltransferase inhibitor 5-azacitidine in common human epithelial cancers","volume":"5","author":"Li","year":"2014","journal-title":"Oncotarget"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1038\/s41375-018-0070-8","article-title":"Hypomethylating agents in combination with immune checkpoint inhibitors in acute myeloid leukemia and myelodysplastic syndromes","volume":"32","author":"Daver","year":"2018","journal-title":"Leukemia"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"810387","DOI":"10.3389\/fonc.2021.810387","article-title":"Hypomethylating Agent-Based Combination Therapies to Treat Post-Hematopoietic Stem Cell Transplant Relapse of Acute Myeloid Leukemia","volume":"11","author":"Ciotti","year":"2022","journal-title":"Front. Oncol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1158\/2159-8290.CD-18-0774","article-title":"Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed\/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study","volume":"9","author":"Daver","year":"2019","journal-title":"Cancer Discov."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1007\/s11864-020-00765-5","article-title":"Treatment of Relapsed Acute Myeloid Leukemia","volume":"21","author":"Thol","year":"2020","journal-title":"Curr. Treat. Options Oncol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1016\/S1470-2045(21)00494-0","article-title":"Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): A single-arm, phase 1b and randomised, phase 2 trial","volume":"22","author":"DiNardo","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"2526","DOI":"10.1056\/NEJMoa2004444","article-title":"Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission","volume":"383","author":"Wei","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"3669","DOI":"10.1182\/blood-2003-11-3775","article-title":"Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia","volume":"103","author":"Smith","year":"2004","journal-title":"Blood"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1182\/hematology.2019000058","article-title":"The growing landscape of FLT3 inhibition in AML","volume":"2019","author":"Smith","year":"2019","journal-title":"Educ. Program Am. Soc. Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1056\/NEJMoa1614359","article-title":"Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation","volume":"377","author":"Stone","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1056\/NEJMoa1902688","article-title":"Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML","volume":"381","author":"Perl","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1182\/blood-2021-145379","article-title":"Phase 3, Open-Label, Randomized Study of Gilteritinib and Azacitidine Vs Azacitidine for Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia in Patients Ineligible for Intensive Induction Chemotherapy","volume":"138","author":"Wang","year":"2021","journal-title":"Blood"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1200\/JCO.19.03345","article-title":"Sorafenib Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia With FLT3-Internal Tandem Duplication Mutation (SORMAIN)","volume":"38","author":"Burchert","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"29131","DOI":"10.18632\/oncotarget.8675","article-title":"Dual inhibition of AKT\/FLT3-ITD by A674563 overcomes FLT3 ligand-induced drug resistance in FLT3-ITD positive AML","volume":"7","author":"Wang","year":"2016","journal-title":"Oncotarget"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"3004","DOI":"10.3389\/fimmu.2019.03004","article-title":"Neoantigens in Hematological Malignancies-Ultimate Targets for Immunotherapy?","volume":"10","author":"Roerden","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1182\/blood.2020007233","article-title":"Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: A phase 1 study","volume":"137","author":"Stein","year":"2021","journal-title":"Blood"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"3531","DOI":"10.2217\/fon-2019-0373","article-title":"Glasdegib plus intensive\/nonintensive chemotherapy in untreated acute myeloid leukemia: BRIGHT AML 1019 Phase III trials","volume":"15","author":"Cortes","year":"2019","journal-title":"Future Oncol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1038\/nm.3788","article-title":"Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia","volume":"21","author":"Chan","year":"2015","journal-title":"Nat. Med."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.1111\/bjh.16268","article-title":"FLA-IDA salvage chemotherapy combined with a seven-day course of venetoclax (FLAVIDA) in patients with relapsed\/refractory acute leukaemia","volume":"188","author":"Shahswar","year":"2020","journal-title":"Br. J. Haematol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1200\/JCO.20.03736","article-title":"Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia","volume":"39","author":"DiNardo","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"403","DOI":"10.3324\/haematol.2020.259531","article-title":"APR-246 induces early cell death by ferroptosis in acute myeloid leukemia","volume":"107","author":"Birsen","year":"2021","journal-title":"Haematologica"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1038\/s41416-021-01561-0","article-title":"APR-246 induces apoptosis and enhances chemo-sensitivity via activation of ROS and TAp73-Noxa signal in oesophageal squamous cell cancer with TP53 missense mutation","volume":"125","author":"Kobayashi","year":"2021","journal-title":"Br. J. Cancer"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2020-134942","article-title":"Preliminary Data on a Phase 1\/2A First in Human Study of the Menin-KMT2A (MLL) Inhibitor KO-539 in Patients with Relapsed or Refractory Acute Myeloid Leukemia","volume":"136","author":"Wang","year":"2020","journal-title":"Blood"},{"key":"ref_117","unstructured":"Tucker, N. (2022, March 08). SNDX-5613 Demonstrates Robust Clinical Activity in MLL-Rearranged and NPM1c-Mutant R\/R Acute Leukemia. Targeted Oncology. Available online: https:\/\/www.targetedonc.com\/view\/sndx-5613-demonstrates-robust-clinical-activity-in-mll-rearranged-and-npm1c-mutant-r-r-acute-leukemia."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"296","DOI":"10.2174\/1389450116666150223120005","article-title":"Novel Antigen Targets for Immunotherapy of Acute Myeloid Leukemia","volume":"18","author":"Goswami","year":"2017","journal-title":"Curr. Drug Targets"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","article-title":"Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia","volume":"133","author":"DiNardo","year":"2019","journal-title":"Blood"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"5327","DOI":"10.1038\/s41467-020-19119-8","article-title":"Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics","volume":"11","author":"Morita","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/s41586-020-2864-x","article-title":"Single-cell mutation analysis of clonal evolution in myeloid malignancies","volume":"587","author":"Miles","year":"2020","journal-title":"Nature"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/6\/3304\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:39:13Z","timestamp":1760135953000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/6\/3304"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,18]]},"references-count":121,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2022,3]]}},"alternative-id":["ijms23063304"],"URL":"https:\/\/doi.org\/10.3390\/ijms23063304","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,18]]}}}